Meta-analysis of Gynostemma pentaphyllum for glycemic control in diabetes patients

IntroductionGynostemma pentaphyllum (Thunb.) Makino is a traditional “medicine food homology” plant widely consumed in Asia to promote health. Its safety profile makes it a promising diabetes candidate. This study systematically evaluates its efficacy in glycemic control and elucidates its mechanisms of action.MethodsWe conducted a meta-analysis of clinical studies from PubMed, CNKI, and Embase. Random-effects models calculated pooled mean differences (MD) for fasting plasma glucose (FPG), 2-h postprandial glucose (2hPG), and glycated hemoglobin (HbA1c). A systematic review also summarized its antidiabetic mechanisms.ResultsEight studies involving 584 patients were included. Gynostemma pentaphyllum significantly reduced FPG (MD = −0.79 mmol/L, 95% CI = −1.08 to −0.51), HbA1c (MD = −1.01%, 95% CI = −1.41 to −0.61), and 2hPG (MD = −0.90 mmol/L, 95% CI = −1.95 to −0.15). Long-term and monotherapy treatments showed superior efficacy. The mechanistic review revealed hypoglycemic effects via multiple pathways, including enhanced glucose uptake, reduced glucose production, increased insulin secretion, and improved insulin resistance.DiscussionCombined clinical and mechanistic findings demonstrate that Gynostemma pentaphyllum provides effective glycemic control through multi-target pharmacological mechanisms, solidifying its potential as a comprehensive therapeutic approach for diabetes management.